A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Hydrocodone/paracetamol (Primary) ; VX 993 (Primary)
- Indications Acute pain
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 16 Jan 2025 Planned End Date changed from 1 Oct 2025 to 16 Oct 2025.
- 16 Jan 2025 Planned primary completion date changed from 1 Oct 2025 to 16 Oct 2025.
- 14 Nov 2024 Status changed from not yet recruiting to recruiting.